Drugs / rDEN3/4delta30(ME)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00375726 | Oct 2006 → Sep 2008 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN3/4delta30(ME) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00375726 ↗ |
| Modality | Vaccine | “The rDEN3/4delta30(ME) vaccine is a live attenuated dengue virus vaccine” NCT00375726 ↗ |
| Route | Subcutaneous | “One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10\^3 PFU dose) into the deltoid region of either arm.” NCT00375726 ↗ |